Sanofi-aventis (SNY) Announces FDA Approval of Nasacort AQ(R) Nasal Spray for Children
Sanofi-aventis (NYSE: SNY) announced today the U.S. FDA has approved Nasacort AQ Nasal Spray for children aged 2-5 years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis.
The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal symptoms of year-round allergies in children between two and five years. This is the first and largest placebo- controlled trial designed to specifically investigate both the efficacy and safety of an intranasal corticosteroid vs. placebo in 2-5 years of age group.
Sanofi-Aventis engages in the research, development, manufacture, and marketing of healthcare products worldwide.
Create E-mail AlertRelated Categories
Corporate NewsFDA
Stocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
